Joseph Pruner, MD
Internal Medicine · Waterbury, CTNPI 1427493048
Payments from drug & device makers
Across 1,188 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Bayer$3K
- Amarin Pharma, Inc.$2K
- AbbVie$2K
- Amgen$1K
- Boston Scientific$1K
- plus $8K from 33 others
What the payments were for
- Food & beverage$19,29299%
- Education$1641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 188 | $2,695 |
| Bayer | 116 | $2,523 |
| Amarin Pharma, Inc. | 134 | $2,150 |
| AbbVie(2 entities) | 135 | $1,794 |
| Amgen | 83 | $1,444 |
| Boston Scientific | 68 | $1,221 |
| AstraZeneca | 60 | $1,192 |
| GSK | 42 | $770 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $683 |
| Merck | 59 | $652 |
| Sanofi-aventis U.S. LLC | 29 | $548 |
| Pfizer | 37 | $511 |
| Boehringer Ingelheim | 31 | $489 |
| Lilly USA, LLC | 25 | $453 |
| Johnson & Johnson | 32 | $311 |
| Abbott | 12 | $284 |
| Astellas Pharma US Inc | 11 | $258 |
| Antares Pharma, Inc. | 12 | $237 |
| Assertio Therapeutics, Inc. | 22 | $234 |
| Exact Sciences | 8 | $216 |
| Eisai Inc. | 6 | $94 |
| Avanir Pharmaceuticals, Inc. | 5 | $82 |
| Lundbeck LLC | 3 | $63 |
| Dexcom, Inc. | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| Halozyme Inc | 2 | $47 |
| Azurity Pharmaceuticals, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Aytu Biopharma, Inc. | 3 | $41 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| MDD US Operations, LLC | 2 | $26 |
| Viatris Specialty LLC | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Dermira, Inc. | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
How this compares
$19,456 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 254 | $427,481 |
| RybelsusSemaglutide | 83 | $174,985 |
| Tresiba Flextouch U-200Insulin Degludec | 114 | $84,198 |
| FarxigaDapagliflozin Propanediol | 74 | $81,896 |
| JardianceEmpagliflozin | 73 | $81,772 |
| JanuviaSitagliptin Phosphate | 56 | $65,143 |
| KerendiaFinerenone | 33 | $57,999 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $57,134 |
| LinzessLinaclotide | 40 | $46,354 |
| EliquisApixaban | 53 | $45,390 |
| ProliaDenosumab | 25 | $43,443 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $33,057 |
| XareltoRivaroxaban | 19 | $29,767 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $28,303 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $27,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,695 | $602,467337 claims |
| MerckJanuvia, Janumet, Janumet Xr, Belsomra | $652 | $176,109165 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat | $489 | $120,459127 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,192 | $115,690143 claims |
| BayerKerendia | $2,523 | $57,99933 claims |
| AbbVieLinzess, Synthroid | $1,794 | $52,506116 claims |
| PfizerEliquis | $511 | $45,39053 claims |
| AmgenProlia | $1,444 | $43,44325 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $770 | $36,26754 claims |
| Johnson & JohnsonXarelto | $311 | $29,76719 claims |
| Astellas Pharma US IncMyrbetriq | $258 | $26,61334 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $43 | $23,69212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Waterbury
- Joseph SouferWaterbury$21.5M
- Elie HelouWaterbury$184K
- Oltjon AlbajramiWaterbury$57K
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.